Company:  TROVAGENE, INC. (TROV)
Form Type:  8-K
Filing Date:  4/16/2018 
CIK:  0001213037 
Address:  11055 FLINTKOTE AVENUE 
City, State, Zip:  SAN DIEGO, California 92121 
Telephone:  858-217-5420 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.80  
Change: 
0.003 (0.39%)  
Trade Time: 
Aug 16  
Market Cap: 
$14.06M
Trade TROV now with 

© 2018  
Description of Business
We are a clinical-stage, precision medicine oncology therapeutics company. Our primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® ("PCM") technology in tumor genomics. Our lead drug candidate, PCM-075, is a Polo-like Kinase 1 ("PLK1") selective adenosine triphosphate ("ATP") competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia ("AML"), metastatic Castration-Resistant Prostate Cancer ("mCRPC") and other hematologic and solid tumor cancers. On March 15, 2017, we announced the licensing of PCM-075, a PLK1 inhibitor, from Nerviano Medical Sciences S.r.l.
Register and access this filing in:     
  FORM 8-K
    SECTION 8 OTHER EVENTS
      Item 8.01 Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits
    SIGNATURE
  EXHIBIT 99.1